RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-8.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$3.57B
AUM Growth
+$3.57B
(-15%)
Cap. Flow
+$230K
Cap. Flow
% of AUM
0.01%
Top 10 Holdings %
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$75.7M |
| 2 |
Merck
MRK
|
$60.7M |
| 3 |
Beam Therapeutics
BEAM
|
$60.5M |
| 4 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$56.7M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$52.7M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$116M |
| 2 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$109M |
| 3 |
Boston Scientific
BSX
|
$73.8M |
| 4 |
Centene
CNC
|
$43.3M |
| 5 |
HCA Healthcare
HCA
|
$42.2M |
Sector Composition
| 1 | Healthcare | 97.84% |
| 2 | Industrials | 0.87% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $249M | 6.98% | 11,216,809 | – | – |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $233M | 6.52% | 25,181,500 -28,464 | -0.1% | -$263K |
|
|
DCPH
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $211M | 5.91% | 5,116,263 +406,765 | +9% | +$16.7M |
|
4
Biogen
BIIB
$19.4B
| $186M | 5.23% | 589,300 +131,800 | +29% | +$41.7M |
|
|
IGMS
5
DELISTED
IGM Biosciences
IGMS
| $177M | 4.95% | 3,144,000 | – | – |
|
6
argenx
ARGX
$43.6B
| $143M | 4% | 1,082,070 -71,162 | -6% | -$9.37M |
|
|
MNTA
7
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $141M | 3.95% | 5,175,008 +1,937,308 | +60% | +$52.7M |
|
|
EPZM
8
DELISTED
Epizyme, Inc
EPZM
| $136M | 3.81% | 8,768,475 +22,442 | +0.3% | +$348K |
|
|
PRNB
9
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $134M | 3.76% | 2,261,088 -461,300 | -17% | -$27.4M |
|
|
ALLK
10
DELISTED
Allakos
ALLK
| $132M | 3.71% | 2,976,928 -56,598 | -2% | -$2.52M |
|
11
uniQure
QURE
$896M
| $132M | 3.69% | 2,773,525 +220,200 | +9% | +$10.4M |
|
12
Aprea Therapeutics
APRE
$9.09M
| $78.9M | 2.21% | 2,268,718 | – | – |
|
13
Regenxbio
RGNX
$451M
| $75.7M | 2.12% | 2,338,466 -169,920 | -7% | -$5.5M |
|
|
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
| $75.7M | 2.12% | +655,700 | New | +$75.7M |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $70.6M | 1.98% | 706,426 -232,738 | -25% | -$23.3M |
|
|
16
Merck
MRK
$210B
| $60.7M | 1.7% | +788,500 | New | +$60.7M |
|
|
17
Beam Therapeutics
BEAM
$1.66B
| $60.5M | 1.7% | +3,359,258 | New | +$60.5M |
|
18
UnitedHealth
UNH
$281B
| $60.1M | 1.69% | 241,100 +38,000 | +19% | +$9.48M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $57.1M | 1.6% | 16,733,879 +2,093,919 | +14% | +$7.14M |
|
20
Tandem Diabetes Care
TNDM
$845M
| $56.7M | 1.59% | 881,266 -290,966 | -25% | -$18.7M |
|
|
ONEM
21
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $56.7M | 1.59% | +3,123,384 | New | +$56.7M |
|
22
Novartis
NVS
$245B
| $53.9M | 1.51% | 653,600 +80,500 | +14% | +$6.64M |
|
23
Cigna
CI
$80.3B
| $53.3M | 1.49% | 300,600 +153,100 | +104% | +$27.1M |
|
24
Stoke Therapeutics
STOK
$1.08B
| $49.6M | 1.39% | 2,165,938 +1,145,160 | +112% | +$26.2M |
|
|
25
Centene
CNC
$14.3B
| $49M | 1.37% | 824,090 -728,508 | -47% | -$43.3M |
|